Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling
暂无分享,去创建一个
Pavel Stavrev | R. Ruggieri | S. Naccarato | Ruggero Ruggieri | Stefania Naccarato | Nadejda Stavreva | N. Stavreva | Pavel Vassilev Stavrev
[1] R K Ten Haken,et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. , 1999, Lung cancer.
[2] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[3] K L Lindsley,et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.
[4] Philippe Lambin,et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] J. Galvin,et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.
[6] A. Nahum,et al. Severe hypofractionation: Non-homogeneous tumour dose delivery can counteract tumour hypoxia , 2010, Acta oncologica.
[7] R. Ruggieri,et al. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia. , 2004, Physics in medicine and biology.
[8] J. Moulder,et al. The steepness of the dose-response curve in radiation therapy. Theoretical considerations and experimental results. , 1975, Radiology.
[9] Lech Papiez,et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[10] J. Galvin,et al. Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy. , 2012, International journal of radiation oncology, biology, physics.
[11] X Allen Li,et al. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. , 2004, Physics in medicine and biology.
[12] R. Milardo,et al. Time-dose relationships for the cure of an experimental rat tumor with fractionated radiation. , 1976, International journal of radiation oncology, biology, physics.
[13] Lech Papiez,et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.
[14] R. Ruggieri,et al. Applying a hypoxia-incorporating TCP model to experimental data on rat sarcoma. , 2012, International journal of radiation oncology, biology, physics.
[15] Suresh Senan,et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. , 2012, International journal of radiation oncology, biology, physics.
[16] Lech Papiez,et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Dunlop,et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Nahum,et al. The impact of hypofractionation on simultaneous dose-boosting to hypoxic tumor subvolumes. , 2006, Medical physics.
[19] Suresh Senan,et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.
[20] Andrea Bezjak,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.